Diabetes Impact on Cancer Outcomes

Diabetes, particularly type 2, intersects with cancer in complex ways that influence disease progression, treatment tolerance and long-term survival. Chronic hyperglycaemia and insulin resistance can create a pro-tumourigenic environment through inflammatory mediators, altered metabolism and vascular dysfunction. Among cancer patients, pre-existing diabetes is consistently associated with increased all-cause and cancer-specific mortality, higher rates of treatment-related complications and poorer quality of life. Conversely, certain cancer therapies and surgical interventions may precipitate new-onset diabetes, underscoring the bidirectional nature of the relationship. Global cohort studies and meta-analyses highlight variation by cancer type, stage and demographic factors, emphasising the need for integrated management strategies. Early identification of glycaemic abnormalities, optimisation of metabolic control and targeted lifestyle interventions emerge as cornerstones for improving outcomes in this growing population of comorbid patients.

Research from Nature Portfolio

A large longitudinal analysis of individuals with type 2 diabetes and incident breast, lung, colorectal or prostate cancer revealed that the coexistence of diabetes and cancer nearly quadruples all-cause mortality compared with diabetes alone. Modifiable risk factors—particularly smoking and low physical activity—were the strongest predictors of death, whereas glycosylated haemoglobin, lipid levels, hypertension and body mass index had only weak associations with survival. These findings suggest that lifestyle interventions may offer more immediate survival benefits than strict biochemical targets and should be prioritised in multidisciplinary care pathways for patients facing dual diagnoses.

Diabetes Impact on Cancer Outcomes publication trend

The graph below shows the total number of articles in diabetes impact on cancer outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Type 2 diabetes: A chronic metabolic disorder characterised by insulin resistance and relative insulin deficiency, leading to elevated blood glucose.

Hyperglycaemia: A condition of abnormally high blood glucose levels, which can promote inflammation and vascular damage.

Incidence rate: The number of new cases of a disease in a specified population over a defined period.

Hazard ratio: A measure comparing the probability of an event occurring in two groups over time.

Cohort study: An observational design following a group with shared characteristics to assess outcomes over time.

Meta-analysis: A statistical method that combines results from multiple independent studies to derive pooled estimates.

References

1. The impact of surgery and oncological treatment on risk of type 2 diabetes onset in patients with colorectal cancer: nationwide cohort study in Denmark. eLife (2024).
2. Analysis of the Incidence of Type 2 Diabetes, Requirement of Insulin Treatment, and Diabetes-Related Complications among Patients with Cancer. Cancers (2023).
3. Diabetes-related risk factors and survival among individuals with type 2 diabetes and breast, lung, colorectal, or prostate cancer. Scientific Reports (2024).
4. Higher Incidence of Diabetes in Cancer Patients Compared to Cancer-Free Population Controls: A Systematic Review and Meta-Analysis. Cancers (2022).